NVS

Novartis AG (NVS)

Last Price$109.41.9%
Market Cap$217.3B
LTM ROIC - WACC
10.8%
5Y avg
6.0%
Drug Manufacturers - General industry median
6.1%
Stock quality & Intrinsic value
7/10
0.2% undervalued

Novartis AG ROIC - WACC

Annual
Quarterly
LTM
Industry median
Company stand-alone
NVS
Healthcare
Crunching data... Almost there!
Dec'05Dec'06Dec'07Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
ROIC - WACC
16.5%
12.7%
7.7%
11.3%
12.6%
8.1%
4.6%
5.1%
4.7%
6.2%
4.2%
2.9%
3.2%
2.2%
3.6%
6.2%
23.7%
2.9%
5.5%
11.1%
NVS
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for NVS and see if it's the right time to invest.
Dive in

Novartis AG (NVS) ROIC - WACC comparison analysis

Crunching data... Almost there!

NVS key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is Novartis AG's ROIC - WACC?

As of today, Microsoft Corp's last 12-month ROIC - WACC is 10.8%, based on the financial report for Dec 31, 2024 (Q4 2024). The average annual ROIC - WACC for Novartis AG have been 6.3% over the past three years, and 6.3% over the past five years.

2) Is Novartis AG's ROIC - WACC Good?

As of today, Novartis AG's ROIC - WACC is 10.8%, which is higher than industry median of 6.1%. It indicates that Novartis AG's ROIC - WACC is Good.

3) How does Novartis AG's ROIC - WACC compare to its peers?

As of today, Novartis AG's ROIC - WACC is 10.8%, which is higher than peer median of 5.5%. The list of peers includes LLY, MRK, GILD, PFE, BMY, AMGN, JNJ, ABBV, SNY, AZN.